Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
Completed
AstraZeneca
Phase 3
2007-02-01
This trial evaluates the rate of onset of bronchodilator action of aclidinium bromide
compared to placebo and tiotropium in patients with severe COPD after a single dose
treatment.
A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Completed
AstraZeneca
Phase 3
2007-07-01
This study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in
reducing resting and dynamic lung hyperinflation in patients with moderate to severe COPD. It
was 9 weeks in duration, consisting of; a 2-week run-in period, 6 weeks of double-blind
treatment, and a 1-week follow-up phone call. All patients meeting the eligibility criteria
were randomized to one of two treatment groups: aclidinium bromide or placebo.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
